Celldex ended development in prurigo nodularis after its KIT inhibitor barzolvolimab missed efficacy measures in a phase II study, according to a company update. The decision follows investor scrutiny on prior data and shifts attention toward planned phase III readouts in other chronic itch indications, with management framing continued development efforts around the remaining program strategy.